KIF5B-RET融合基因与非小细胞肺癌  

KIF5B-RET fusion gene and non-small cell lung cancer

作　　者：韩英[1] 成志勇[1] 蒋丽媛[1] 

机构地区：[1]保定市第一医院肿瘤内科,河北保定071000

出　　处：《临床肿瘤学杂志》2013年第2期183-186,共4页Chinese Clinical Oncology

摘　　要：肺癌是全世界范围死亡率最高的肿瘤。近年来,靶向治疗成为肺癌研究的热点。2012年研究发现肺癌中存在一种新的融合基因KIF5B-RET,其阳性患者多为不吸烟或很少吸烟的腺癌患者。其存在与其他已知的基因改变如EGFR、K-Ras、ALK等相互排斥,提示KIF5B-RET是一种新的致癌驱动突变,有可能成为非小细胞肺癌个体化诊断与治疗的一个分子靶点。Lung cancer is the leading cause of mortality in cancer worldwide. Molecular targeted therapy is the hotpot of lung cancer study in recent years. In 2012, a novel fusion gene KIFSB-RET was identified in non-small cell lung cancer. This fusion gene is more frequently detected in the lung adenocarcinoma, with no or little history of cigarette smoking. The mutually exclusive nature of the RET fusions and other oncogenic alterations such as EGFR, K-Ras,ALK, etc. , suggests that the KIFSB-RET fusion is a new driver mutation. It could be a promising molecular target for the personalized diagnosis and treatment of non-small cell lung cancer.

关 键 词：KIF5B—RET 非小细胞肺癌 融合基因 

分 类 号：R734.2[医药卫生—肿瘤]